Diagnosis of early-stage non-small cell lung cancer using DNA methylation in tissue and plasma.

ABSTRACT: DNA methylation is a key epigenetic alteration in tumorigenesis, but its diagnostic value in early-stage lung cancer remains unclear. In this study, tissue and plasma samples from patients with lung cancer or benignity were analyzed. Methylation profiles were obtained using bisulfite sequencing and compared with selected lung cancer-specific markers. Diagnostic prediction models were constructed using these markers, with their efficacy assessed by sensitivity, specificity and area under the curve (AUC). In the tissue cohort, 276 markers were found to be significantly differentially methylated in lung cancer (FDR < 0.05). A diagnostic prediction model using six markers showed promising performance in both the training cohort (sensitivity = 90%; specificity = 97%; AUC = 0.988) and the valida

SUBMITTER: Li L 

PROVIDER: S-EPMC12361987 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature